Q4 2025
Released Feb 20, 2026, before the open
10-K filed Mar 10, 2026, 69 days after period end · 0001193125-26-100432
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$2.80M-$2.80M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$3,092,402N/M
Operating Cash Flowderived-$2,016,797N/M
Free Cash Flowderived-$2,016,797N/M
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022 |
|---|---|---|---|---|
| Net Income | -$2.80M | -$2.81M | -$2.06M | -$2.92M |
| EPS Diluted | — | — | — | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Medicinova Inc · CIK 1226616 · Engraved from SEC EDGAR